In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adimab LLC

www.adimab.com

Latest From Adimab LLC

Deal Watch: Gilead Moves Into Kidney Disease Via Goldfinch Collaboration

Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.

Deals Business Strategies

Tizona Lands AbbVie Cancer R&D Deal As New CEO Takes Control

California-based Tizona has begun 2019 by installing a new CEO and winning a lucrative early-stage R&D pact with AbbVie aimed at commercializing cancer therapies targeting the immune system-suppressing enzyme CD39.

Commercial Companies

China's Innovent Biologics Emerges As Immuno-Oncology Competitor With Sintilimab Approval

Medicines regulators have cleared Innovent Biologics's anti-PD-1 therapy, sintilimab, for classical Hodgkin's lymphoma in China, where late-stage studies as a first-line therapy for advanced esopheageal cancer have also just started.

ImmunoOncology China

Finance Watch: Biomatics Closes Second VC Fund; SVB Buys Leerink To Expand Life Science Services

Scrip spoke with Managing Director Julie Sunderland about Biomatics' new $300m fund. Also, Silicon Valley Bank reveals its surprising Leerink buy, Perceptive Advisors raises $675m, Roivant brings in another $200m, and cell and gene therapy financings surge in the third quarter.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Adimab Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Adimab LLC
  • Senior Management
  • Tillman Gerngross, PhD, CEO & Co-Founder
    Guy Van Meter, SVP, Head of Bus. Dev.
    K. Dane Wittrup, PhD, Co-Founder & Chairman of the SAB
    Eric Krauland, PhD, CSO
    Ryan McGovern, SVP, Finance & Ops
    Max Vasquez, SIte Head & SVP Computational Biology
  • Contact Info
  • Adimab LLC
    Phone: (603) 643-7110
    7 Lucent Dr.
    Lebanon, NH 03766
    USA
UsernamePublicRestriction

Register